U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB/A

                                   (Mark One)

|X|   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                For the quarterly period ended October 31, 2003.

          Transition Report Pursuant to 13 or 15(d) of the Securities
                              Exchange Act of 1934

             For the transition period from __________ to __________

                         Commission file number: 0-32801

                                  TISSERA, INC.

        (Exact Name of Small Business Issuer as Specified in Its Charter)

                                BERT Logic, Inc.
                           (Former Name of Registrant)

          Washington                                             91-2034750
(State or other jurisdiction of                               (I.R.S. Employer
incorporation of organization)                               Identification No.)

Galgaley Haplada 11, Third entrance, 3rd floor, Herzlia         46733  Israel
(Address of principal executive offices)                         (Zip Code)

                    Issuer's telephone number: +972-36344107

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes |X|  No |_|

As of January 10, 2005, the registrant had 27,556,914 shares of common stock
outstanding.

Transitional Small Business Disclosure Format (Check one): Yes |_|  No |X|

================================================================================
<PAGE>

                                  TISSERA, INC.

                                      INDEX

Update after inserting financial statements
PART I.  FINANCIAL INFORMATION                                       PAGE NUMBER
------------------------------                                       -----------

Item 1.  Financial statements
                  (unaudited)

         Balance Sheets                                                   2

         Statements of Operations                                         3

         Statements of Changes in Stockholders' Equity                    4

         Statements of cash flows                                         5

         Notes to Financial Statements                                  6-12

Item 2.  Management's Discussion and Analysis and Results of Operations   1

Item 3.  Controls and Procedures                                          3

PART II. OTHER INFORMATION                                                4

Item 1. Legal Proceedings                                                 4

Item 2.  Unregistered Sale of Equity Securities and Use of Proceeds       4

Item 3.  Defaults Upon Senior Securities                                  4

Item 4.  Submission of Matters to Vote of Security Holders                4

Item 5.  Other Information                                                4

Item 6.  Exhibits                                                         4

SIGNATURES                                                                5

<PAGE>

                                  TISSERA INC.

                           (FORMERLY: BERT LOGIC INC.)
                           A development stage company

                              FINANCIAL STATEMENTS

                             AS OF OCTOBER 31, 2003

                                 IN U.S. DOLLARS

                                    UNAUDITED

                                      INDEX

                                                                         Page
                                                                       --------

Balance Sheets                                                            2

Statements of Operations                                                  3

Statements of Changes in Stockholders' Equity (Deficiency)                4

Statements of Cash Flows                                                  5

Notes to Financial Statements                                           6 - 12

                              - - - - - - - - - - -

<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

BALANCE SHEETS
--------------------------------------------------------------------------------
U.S. dollars in thousands

<TABLE>
<CAPTION>
                                                                        October 31,   July 31,
                                                                           2003        2003
                                                                        ---------      -------
                                                                        Restated
                                                                        ---------
                                                                        Unaudited
                                                                        ---------
<S>                                                                      <C>          <C>
     ASSETS

CURRENT ASSETS:
  Cash and cash equivalents                                              $   458      $    --
  Prepaid expenses                                                             9           --
  Assets attributed to discontinued operations                                --            8
                                                                         -------      -------

Total current assets                                                         467            8
                                                                         -------      -------

Total assets                                                             $   467      $     8
                                                                         =======      =======

    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)

CURRENT LIABILITIES
  Related parties - stockholders                                         $     6      $    --
  Other accounts payable and accrued expenses                                113           --
  Liabilities attributed to discontinued operations                           --           18
                                                                         -------      -------

Total liabilities                                                            119           18
                                                                         -------      -------

STOCKHOLDERS' EQUITY (DEFICIENCY):
  Common stock of $ 0.0001 par value each -
    Authorized: 100,000,000 shares as of July 31, 2003 and October 31,
      2003; Issued and outstanding: 18,036,000 shares as of July 31,
      2003 and October 31, 2003                                                2            2
    Preferred stock of $ 0.0001 par value each -
    Authorized: 20,000,000 shares as of July 31, and October 31, 2003;
      Issued and outstanding: 0 shares as of July 31, 2003 and October
      31, 2003                                                                --           --
  Additional paid-in capital                                               2,559           93
  Receipts on account of stock                                             1,102           --
  Accumulated deficit                                                     (3,315)        (105)
                                                                         -------      -------

Total stockholders' equity (deficiency)                                      348          (10)
                                                                         -------      -------

Total liabilities and stockholders equity (deficiency)                   $   467      $     8
                                                                         =======      =======
</TABLE>

The accompanying notes are an integral part of the financial statements.


                                     - 2 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

STATEMENTS OF OPERATIONS
--------------------------------------------------------------------------------
U.S. dollars in thousands (except share and per share data)


<TABLE>
<CAPTION>
                                                                                                                     From
                                                                                                                  May 31, 2000
                                                                                   Three months ended October      (inception
                                                                                                31,               date) through
                                                                                  -----------------------------   October 31,
                                                                                      2003            2002           2003
                                                                                  -------------   -------------   ------------
                                                                                    Restated
                                                                                  -------------
                                                                                                    Unaudited
                                                                                  --------------------------------------------
<S>                                                                               <C>             <C>             <C>
Operating expenses:
  Research and development (including cost related to warrants granted to Yeda
     (see note 3) and to service providers in the amount of $ 1,543 and $ 0 for
     the three months ended October
     31, 2003 and 2002, respectively)                                             $       2,079   $          --   $      2,079
  General and administrative (including cost related to shares
      granted to service providers in the amount of $ 923 and $ 0
      for the three months ended October 31, 2003 and 2002,
      respectively)                                                                       1,145              --          1,145
                                                                                  -------------   -------------   ------------

                                                                                          3,224              --          3,224
Financial income, net                                                                        (1)             --             (1)
                                                                                  -------------   -------------   ------------

Loss from continuing operations                                                           3,223              --          3,223
Income (loss) from discontinued operations                                                   13               3            (92)
                                                                                  -------------   -------------   ------------

Net loss                                                                          $       3,210   $           3   $      3,315
                                                                                  =============   =============   ============

Basic and diluted loss per share from continuing operations                       $       (0.18)  $          --   $      (0.18)
                                                                                  =============   =============   ============

Basic and diluted loss per share from discontinued operations                                --              --             --
                                                                                  =============   =============   ============
Net loss per share                                                                $       (0.18)  $          --   $      (0.18)

                                                                                  =============   =============   ============
Weighted average number of shares used in computing basic and                        18,036,000      18,036,000     18,036,000
   diluted net loss per share
                                                                                  =============   =============   ============

The accompanying notes are an integral part of the financial statements.
</TABLE>


                                     - 3 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
--------------------------------------------------------------------------------
U.S. dollars in thousands (except share data)

<TABLE>
<CAPTION>
                                                                                                 Deficit
                                                                                                accumulated        Total
                                                 Stock capital         Additional   Receipts     during the    stockholders'
                                             -----------------------    paid-in    on account   development        equity
                                               Number      Amount       capital     of stock       stage        (deficiency)
                                             -----------------------   ----------   ----------    ----------    ----------

<S>                                          <C>          <C>          <C>          <C>           <C>           <C>
Balance as of May 31, 2000                           --   $       --   $       --   $       --    $       --    $       --

Shares issued for cash on May 31, 2000       15,036,000            2            8           --            --            10
Net loss                                             --           --           --           (5)           (5)
                                             -----------------------   ----------   ----------    ----------    ----------

Balance as of July 31, 2000                  15,036,000            2            8           --            (5)            5

Shares issued for cash on July 17, 2001       3,000,000         *)--           40           --            --            40
Contribution of capital                              --           --           15           --            --            15
Net loss                                             --           --           --           --           (30)          (30)
                                             -----------------------   ----------   ----------    ----------    ----------

Balance as of July 31, 2001                  18,036,000            2           63           --           (35)           30

Contribution of capital                              --           --           15           --            --            15
Net loss                                             --           --           --           --           (39)          (39)
                                             -----------------------   ----------   ----------    ----------    ----------

Balance as of July 31, 2002                  18,036,000            2           78           --           (74)            6

Contribution of capital                              --           --           15           --            --            15
Net loss                                             --           --           --           --           (31)          (31)
                                             -----------------------   ----------   ----------    ----------    ----------

Balance as of July 31, 2003                  18,036,000            2           93           --          (105)          (10)

Receipts on account of stock                         --           --           --        1,102            --         1,102
Stock based compensation related
  to warrants and shares granted
  to Yeda and to service
  providers- Restated                                --           --        2,466           --            --         2,466
Net loss-Restated                                    --           --           --           --        (3,210)       (3,210)
                                             -----------------------   ----------   ----------    ----------    ----------

Balance as of October 31,
  2003-Restated                              18,036,000   $        2   $    2,559   $    1,102    $   (3,315)   $      348
                                             ==========   ==========   ==========   ==========    ==========    ==========
</TABLE>

*) Represents an amount lower than $ 1.

The accompanying notes are an integral part of the consolidated financial
statements.


                                     - 4 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

STATEMENTS OF CASH FLOWS
--------------------------------------------------------------------------------
U.S. dollars in thousands

<TABLE>
<CAPTION>
                                                                                                          From
                                                                                                       May 31, 2000
                                                                        Three months ended October      (inception
                                                                                     31,               date) through
                                                                       -----------------------------   October 31,
                                                                           2003            2002           2003
                                                                       -------------   -------------   ------------
                                                                         Restated
                                                                       -------------
                                                                                         Unaudited
                                                                       --------------------------------------------
<S>                                                                      <C>              <C>             <C>
Cash flows from operating activities:
  Net loss                                                               $(3,210)         $    --         $(3,315)
  Adjustments required to reconcile net loss to net cash provided by
     (used in) operating activities:
  Expenses related to warrants and shares granted to Yeda and to
    service providers                                                      2,466               --           2,466
   Increase in prepaid expenses                                               (9)              --              (9)
   Increase in accounts payable and accrued expenses                         114               --             114
                                                                         -------          -------         -------

Net cash used in continuing operating activities                            (639)              --            (744)
Net cash provided by (used in) discontinued operating activities             (10)               8              80
                                                                         -------          -------         -------

Total net cash provided by (used in) operating activities                   (649)               8            (664)
                                                                         -------          -------         -------

Cash flows from investing activities:
  Net cash used in discontinued investing activities                          --               --             (15)
                                                                         -------          -------         -------

Total net cash used in investing activities                                   --               --             (15)
                                                                         -------          -------         -------

Cash flows from financing activities:
  Receipts on account of stock                                             1,102               --           1,102
                                                                         -------          -------         -------

Net cash provided by continuing financing activities                       1,102               --           1,102
Net cash flows provided by discontinued financing activities                  --               20              35
                                                                         -------          -------         -------

Total net cash provided by financing activities                            1,102               20           1,137
                                                                         -------          -------         -------

Increase in cash and cash equivalents                                        453               28             458
Cash and cash equivalents at beginning of period                               5                7              --
                                                                         -------          -------         -------

Cash and cash equivalents at end of period                               $   458          $    35         $   458
                                                                         =======          =======         =======

Non-cash financing activities:
Licenses purchased against notes payable                                 $    --          $    --         $    28
                                                                         =======          =======         =======
</TABLE>

The accompanying notes are an integral part of the financial statements.


                                     - 5 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 1:- GENERAL

      a.    Tissera Inc. ("the Company") was incorporated under the laws of the
            State of Washington on May 31, 2000.

            On September 4, 2003, the former president of Bert Logic Inc.
            completed a stock purchase agreement with the Company's existing
            stockholders, who purchased 15,000,000 shares of the currently
            issued and outstanding 18,036,000 shares of the Company's Common
            stock. In connection with the consummation of the transaction, the
            president of the Company resigned as president and sole director of
            the Company. Pursuant to the agreement, the Company entered into an
            amended license agreement to sell Bit Error Rate Testers on a
            worldwide non-exclusive basis. In exchange, the Company obtained
            forgiveness of the remaining promissory note of $ 10, and accrued
            interest of $ 2. Also, in connection with the transaction, the
            former president of the Company agreed to forgive his stockholder
            loan, in the amount of $ 2.

            Following the share purchase agreement dated September 4, 2003, the
            management of the Company decided to dispose all activities related
            to the sales of Bit Error Rate Testers, used for the integrity and
            reliability of communication channels. The discontinuation of that
            activity was accounted for as discontinued operations under the
            provision of Statement of Financial Accounting Standards ("SFAS")
            No. 144, "Accounting for the Impairment or Disposal of Long-Lived
            Assets".

            On October 8, 2003, the Company entered into a research and license
            agreement with Yeda Research and Development Company Limited
            ("Yeda"), according to which Yeda provided the Company with a
            worldwide, exclusive license to develop, manufacture and sell Yeda's
            tissue transplant technologies (see also Note 3).

            On October 9, 2003, the Company's Board of Directors resolved to
            change the name of the Company from Bert Logic, Inc. to "Tissera,
            Inc."

      b.    On October 27, 2003 the Company incorporated a wholly-owned
            subsidiary, Tissera Ltd. The subsidiary had not yet commenced
            operations as of the balance sheet date.

      c.    Going concern considerations (Restated):

            The Company's ability to continue to operate as a going concern is
            dependent on its ability to maintain its key technology license (see
            Note 3), a favorable outcome of the legal proceeding with investors
            (see Note 6) and its ability to generate sufficient cash flows meet
            its obligations on a timely basis, to obtain additional financing
            and to ultimately attain profitability. The process of developing
            commercial products will require significant additional expenditures
            for research and development, maintaining the key technology
            license, pre-clinical testing and clinical trials, as well as
            regulatory approval. These activities, together with general and
            administrative expenses, are expected to result in substantial
            operating losses in the foreseeable future. In the event the Company
            will lose its key technology license, will have unfavorable outcome
            of its legal proceeding with investors, or is unable to successfully
            raise capital and generate revenues, it is unlikely that the Company
            will have sufficient cash flows and liquidity to finance its
            business operations as currently contemplated. Accordingly, the
            Company will likely reduce general and administrative expenses and
            cease or delay development projects until it is able to obtain
            sufficient financing.


                                     - 6 -
<PAGE>


                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 1:- GENERAL (cont.)

            In addition, if the Company will not be able to maintain its key
            technology license, the company's current research and development
            operations will cease.

            The financial statements do not include any adjustments to reflect
            the possible future effect on the recoverability and classification
            of assets or the amounts and classification of liabilities that may
            result from the outcome of these uncertainties.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

            These financial statements have been prepared as of October 30,
            2003, and for the three months then ended ("interim financial
            statements"). These financial statements should be read in
            conjunction with the Company's audited annual financial statements
            and accompanying notes as of July 31, 2003 and for the year then
            ended. The significant accounting policies applied in the annual
            financial statements of the Company as of July 31, 2003, are applied
            consistently in these financial statements. In addition, the
            following accounting policies were adopted in the current reported
            period:

            a.    Financial statements in U.S. dollars:

                  The functional and reporting currency of the Company is the
                  U.S. dollar.

                  The functional currency of the Company is the U.S dollar
                  ("dollar") since the dollar is the currency of the primary
                  economic environment in which the Company has operated and
                  expects to continue to operate in the foreseeable future.

            b.    Research and development costs:

                  Research and development costs are charged to expenses as
                  incurred.

            c.    Basic and diluted net loss per share:

                  Basic net loss per share is computed based on the weighted
                  average number of shares outstanding during each period.
                  Diluted net loss per share is computed based on the weighted
                  average number of shares outstanding during each period, plus
                  the dilutive potential of the Common stock considered
                  outstanding during the period, in accordance with SFAS No.
                  128, "Earnings per Share."

                  All outstanding share and warrants the Company committed to
                  grant have been excluded from the calculation of the diluted
                  loss per share for the period ended October 31, 2003, because
                  all such securities have an anti-dilutive effect.

            d.    The Company applies SFAS 123 "Accounting for Stock Based
                  Compensation" and EITF 96-18 "Accounting for Equity
                  Instruments That are Issued to Other Than Employees for
                  Acquiring, or in Conjunction with Selling, Goods or Services"
                  ("EITF 96-18") with respect to options and warrants committed
                  to be issued to non-employees. SFAS 123 and EITF 96-18 require
                  the use of an option valuation model to measure the fair value
                  of the options at the grant date.


                                     - 7 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (cont.)

            e.    Recent accounting pronouncements:

                  In May 2003, the FASB issued SFAS No. 150 ("Accounting for
                  Certain Financing Instruments with Characteristics of Both
                  Liabilities and Equity". This Statement established standards
                  for the issuer as to how to classify both liabilities and
                  equity. It requires that an issuer will classify a financial
                  instrument that is within its scope as a liability (or an
                  asset in some circumstances) because that financial instrument
                  embodies an obligation of the issuer. This Statement is
                  effective for financial instruments entered into or modified
                  after May 31, 2003, and otherwise is effective at the
                  beginning of the first interim period beginning after June 15,
                  2003, except for mandatory redeemable financial instruments of
                  nonpublic entities. The Company does not expect that the
                  adoption of this standard will have a material effect on its
                  financial position or results of operations.

                  In January 2003, the FASB issued FIN 46, "Consolidation of
                  Variable Entities " ("FIN 46"). FIN 46 clarifies the
                  application of Accounting Research Bulletin No. 51,
                  "Consolidated Financial Statements" to those entities defined
                  as "Variable Interest Entities" (more commonly referred to as
                  special purpose entities) in which equity investors do not
                  have the characteristics of a "controlling financial interest"
                  or do not have sufficient equity at risk for the entity to
                  finance its activities without additional subordinated
                  financial support from other parties. FIN 46 applies
                  immediately to all variable interest entities created after
                  January 31, 2003 and by the beginning of the first interim or
                  annual reporting period commencing after March 15, 2004 for
                  variable interest entities created prior to February 1, 2003.
                  The Company does not except the adoption of FIN 46 to have a
                  material impact on its results of operations or financial
                  position.

            f.    Interim financial statements:

                  These interim unaudited financial statements have been
                  prepared on the same basis as the annual financial statements
                  and, in the opinion of management, reflect all adjustments
                  necessary to present fairly the Company's financial position,
                  results of operations and cash flows for the periods shown.
                  The results of operations for such periods are not necessarily
                  indicative of the results expected for a full year or for any
                  future period.

NOTE 3:- RESEARCH AND LICENSE AGREEMENT

            On October 8, 2003, the Company entered into a Research and License
            Agreement ("the Agreement") with Yeda. The Company conducts the
            research for a period of three years, at the Weizmann Institute of
            Science, relates to an invention comprising methods of organ
            transplantation utilizing developing nephric tissue. The license
            granted to the Company shall expire at the later of (i) the
            expiration of the patents in the country of sale, or (ii) 15 years
            from the date of receipt of FDA New Drug Approval (in the United
            States), or the equivalent in any other country in which the
            products are sold. In addition, Yeda may terminate the agreement if
            the Company will fail to achieve certain commercialization and
            development achievements, as defined in the agreement.

            The Company committed to grant Yeda, within 120 days of the date on
            which the Agreement is signed, (i) a warrant, exercisable at an
            aggregate exercise price of $ 0.9 to purchase up to 2.23% of the
            issued and outstanding Common stock of the Company immediately
            following the exercise of


                                     - 8 -
<PAGE>

                     n                                              TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 3:- RESEARCH AND LICENSE AGREEMENT (cont.)

            such warrant, and (ii) a warrant, exercisable at an aggregate
            exercise price of $ 1.1 to purchase up to 2.67% of the issued and
            outstanding stock of the Company immediately following the exercise
            of such warrant, provided that the maximum number of shares of
            Common stock that Yeda may exercise under the warrants shall be
            2,315,139 and 2,771,937, respectively (in each case as such number
            of shares of Common stock shall be appropriately adjusted in the
            event of stock splits, stock dividends, capital reorganizations,
            reclassifications, recapitalizations and the like as well as
            issuances or sales by the Company of shares for par value only, for
            a consideration of less than par value and for no consideration, all
            in accordance with the terms and conditions of said warrant, which
            shall be satisfactory to Yeda and to the Company). Each such warrant
            shall be exercisable for a period beginning one year after the date
            on which the Agreement is signed, and ending at the later of (a) one
            year following the termination of the Agreement and (b) 10 years
            after the date on which the Agreement is signed. As of the balance
            sheet date, the Company has not yet granted Yeda the warrants.

            The Company also undertakes to pay to Yeda the following: (i) with
            regard to the first year of the research period (commencing on April
            9, 2003), the amount of $ 450 of which a non-refundable installment
            of $ 225 shall be due and payable on October 9, 2003 and a
            non-refundable installment of $ 225 shall be due and payable on
            January 9, 2004 (These amounts are in addition to $ 450 paid
            earlier, on account of the research for the first year); and (ii)
            with regard to the second and third years of the research period,
            respectively, an amount which shall be not less than $ 900 and not
            more than $ 1,000 per year to be determined by mutual agreement of
            the parties no later than 30 days prior to the commencement of the
            relevant year, in four equal quarterly non-refundable installments,
            payable in advance at the beginning of each three month period
            during such year. If the parties fail to reach agreement within the
            time frame referred to above regarding the amount of the research
            budget payable for the second or third year of the research period
            (as the case may be), then the research budget for such year shall
            be $ 900 and Yeda shall procure the performance of research for such
            reduced amount.

            The Company undertakes to make its best effort to commercialize the
            licensed products. The Company also agreed to pay Yeda a license fee
            of (i) $ 50 per year, to be paid commencing the first year after the
            completion of research and development period; (ii) 4% of net sales
            of all products using the licensed technology; (iii) 33% of all
            sublicense fees for all agreements entered into within one year
            following the Agreement date, and (iv) 16% of all sublicense fees
            for all agreements entered into after such one year period.

NOTE 4:- STOCK SPLIT

            The Company's Board of Directors resolved to effectuate a forward
            split of the Company's Common stock on a 3:1 basis, which occurred
            on November 4, 2003. The additional shares issued pursuant to the
            forward stock split will be fully paid and non-assessable. All new
            shares will have the same par value, voting rights and other rights
            of the Company's common shares. The 3:1 forward stock split is being
            effectuated by increasing the number of issued and outstanding
            shares at the ratio of 3:1. Accordingly, as a result of the forward
            stock split, the Company has 18,036,000 shares outstanding and
            81,964,000 authorized unissued shares, which shares may be issued in
            the future in connection with acquisitions, subsequent financings or
            as determined by the Company's Board of Directors. All share and per
            share data were restated to reflect the stock split effected
            November 4, 2003.


                                     - 9 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 5:-      WARRANTS AND OPTIONS

      a.    The Company is committed to grant 4,722,359 warrants to purchase
            4,722,359 of the Company's Common stock at an exercise price of
            $0.0001 per share, and to issue 2,827,000 shares at no
            consideration. The warrants and shares the Company had committed to
            grant are to service providers in exchange for research and
            development services and general and administrative services.
            4,306,143 warrants and 2,827,000 shares will be fully vested and
            non-forfeitable as of the grant date, and 416,215 warrants will vest
            over a period of three years. The Company accounted for such
            warrants under the provision of EITF 96-18 and the fair value of
            warrants was recorded as research and development expenses and
            general and administrative expenses at the commitment date. As of
            the balance sheet date, the warrants and the shares were not
            granted.

      b.    The Company has committed to grant to certain employees 1,443,829
            options to purchase 1,443,829 of the Company's Common shares. As of
            the balance sheet date, the options have not been granted, and all
            terms and conditions have not yet been determined.

      c.    The Company has committed to grant to certain brokers in conjunction
            with a private placement round (see Note 6) 106,080 warrants to
            purchase 106,080 of the Company's Common stock at an exercise price
            of $0.01 per share and 152,080 shares of Common stock at no
            consideration. As of the balance sheet date, the warrants and shares
            have not been granted.

NOTE 6:- SUBSEQUENT EVENT

      a.    Private placement:

            On February 1, 2004, the Company completed a private placement
            ("PPM") for the sale of 1,767,200 units at a price per unit of $
            1.25. Each unit consists of one Common share and three Common shares
            purchase warrants. The Company granted the investors 5,301,600
            warrants with an exercise price in a range of $ 3.75 - $ 6.00 per
            share. The warrants are exercisable within periods that range from
            six months to three years. The contractual life of the warrants
            ranges from one year to three years.

            On March 18, 2004, the Company completed an additional PPM for the
            sale of 3,142,858 units at a price per unit of $ 1.75. Each unit
            consists of one Common share and three Common shares purchase
            warrants. The Company granted the investors 9,428,574 warrants with
            an exercise price at the range of $ 3.75 - $ 6.00 per share. The
            warrants are exercisable within periods that range from six months
            to three years. The contractual life of the warrants ranges from one
            year to three years. The investors were granted certain registration
            rights. The investors were also granted liquidated damages (as
            defined in the investment agreement) at the rate of 1% of the
            invested amount for each month in which a registration statement is
            not maintained effective with the U.S. Securities and Exchange
            Commission ("SEC"), during a period of 2 years.

            In connection with the second PPM the Company granted to certain
            brokers 172,480 warrants to purchase 172,480 shares of Common stock
            at an exercise price of $ 0.01 per share. In addition, the Company
            granted to these brokers 397,440 warrants to purchase 397,440 shares


                                     - 10 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 6:- SUBSEQUENT EVENT (cont.)

            of Common stock at exercise prices that range between $ 3.75 and $
            6.00 per share. As of July 31, 2004, the brokers exercised 53,800
            warrants into 53,800 shares of Common stock.

      b.    Commitments and contingencies:

            1.    On September 7, 2004, the Board of Directors decided to
                  terminate the employment of the Chief Executive Officer of the
                  Company ("the Former CEO").

            2.    On September 7, 2004, certain shareholders demanded from the
                  Former CEO to repay the Company the amount of $ 1,074 (which
                  is the value of the shares, that the Company issued on April
                  2004, as a result of the Former CEO's cashless exercise of
                  options granted on march 14, 2004, at the date of exercise,
                  and which were sold by the Former CEO), claiming that the
                  exercise of the options was executed before the end of the
                  vesting period. In addition, the shareholders demanded that
                  the Former CEO will pay the Company compensation in the amount
                  of $ 645 for damages. Management of the Company and its legal
                  advisors are of the opinion that the vast majority of the
                  assertions are against the Former CEO and not against the
                  Company. The Company and its legal advisors deny the
                  assertions that may imply to the Company's responsibility and
                  as a result, no provision was recorded in the financial
                  statements.

            3.    On July 19, 2004, the Company received a letter from an
                  investor, which participated in the Company's private
                  placement of securities in March 2004, claiming that the
                  investor was a victim of the Company's misconduct. On
                  September 30, 2004, another investor, which participated in
                  the Company's private placement of securities in March 2004,
                  sent a letter to the Company claiming, among others, that he
                  was a victim of the Company's misconduct. The total investment
                  in the Company's private placement from March 2004 was $
                  5,500. The later investor stated it was prepared to bring
                  claims in the United States District Court for the Southern
                  District of New York if compromise negotiations were not
                  commenced and concluded without delay. The Company has
                  commenced compromise negotiations with all of the investors
                  from the March 2004 private placement. Since the negotiations
                  are in a preliminary stage, the Company cannot estimate at
                  this stage the outcome of such compromise.

NOTE 7:- RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS

The Company restated its financial statements as of October 31, 2003, and for
the three months then ended, for the following reasons:

            1.    Cost related to warrants that the Company committed to grant
                  to Yeda (see Note 3), and warrants and shares that the Company
                  committed to grant certain other service providers, were
                  recorded based on the price per share determined in the
                  private placement conducted in February 2003. In these
                  restated financial statements, the Company recorded these
                  costs based on the market price of its shares as of October
                  31, 2003. In addition, the calculation of the fair value of
                  the warrants that the Company committed to grant Yeda, was
                  revised to reflect issued and outstanding shares of the
                  Company and any options to acquire Company shares for a
                  nominal consideration. Previously, the fair value of shares
                  underling the


                                     - 11 -
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A development stage company

NOTES TO THE FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. dollars in thousands

NOTE 7:- RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS (cont.)

                  warrants was calculated based on all warrants, options and
                  shares the Company committed to grant.

            2.    The Company misinterpreted the Research and License agreement
                  between the Company and Yeda. One factor in calculating the
                  fair value of the warrants that were granted to Yeda is the
                  number of shares underlying the warrants. The number of shares
                  underlying the warrants that the Company committed to grant
                  Yeda (see Note 3), and that was used in the calculation of the
                  fair value of the warrants, was revised to reflect the correct
                  number of the shares according to the agreement.

      The effect of the above changes, related to warrants and shares granted to
      Yeda and to service providers, is as follows:

<TABLE>
<CAPTION>
                                                          Financial statements     Decrease in     Restated   financial
                                                          as reported              expenses        statements
                                                          ---------------------    -----------     --------------------
<S>                                                       <C>                      <C>             <C>
      Research and development expenses                   $ 5,476                  $ 3,933         $ 1,543
      General and administrative expenses                 $ 3,534                  $ 2,611         $   923
      Net loss                                            $ 9,754                  $ 6,544         $ 3,210
      Basic and diluted loss per share from continuing
      operations                                          $ (0.54)                 $  0.36         $ (0.18)
      Basic and diluted loss per share from
      discontinued operations                                  --                       --              --
      Net loss per share                                  $ (0.54)                 $  0.36         $ (0.18)
      Additional paid-in capital                          $(9,103)                 $ 6,544         $(2,559)
      Accumulated deficit                                 $ 9,859                  $ 6,544         $ 3,315
</TABLE>


                                     - 12 -
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

FORWARD LOOKING STATEMENTS - CAUTIONARY STATEMENTS

This Form 10-QSB contains certain "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended (the
"Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"). Specifically, all statements other than statements
of historical facts included in this report regarding Tissera, Inc.'s (the
"Company") financial position, business strategy and plans and objectives of the
Company's management for future operations are forward-looking statements. These
forward-looking statements are based on the beliefs of the Company's management,
as well as assumptions made by and information currently available to the
Company's management. When used in this report, the words "anticipate,"
"believe," "estimate," "expect," "intend," and words or phrases of similar
import, as they relate to the Company or Company management, are intended to
identify forward-looking statements. Such statements (the "cautionary
statements") reflect the current view of the Company's management with respect
to future events and are subject to risks, uncertainties, and assumptions
related to various factors including, without limitation, competitive factors,
general economic conditions, customer relations, relationships with vendors, the
interest rate environment, governmental regulation and supervision, seasonality,
product introductions and acceptance, technological change, changes in industry
practices, and one-time events. Although the Company believes that expectations
are reasonable, it can give no assurance that such expectations will prove to be
correct. Based upon changing conditions, should any one or more of these risks
or uncertainties materialize, or should any underlying assumptions prove
incorrect, actual results may vary materially from those described herein as
anticipated, believed, estimated, expected, or intended. All subsequent written
and oral forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by the applicable
cautionary statements. The Company does not assume any responsibility to
publicly update any of its forward-looking statements regardless whether factors
change as a result of new information, future events, or for any other reason.
The Company advises you to review any additional disclosures made in its 10-QSB,
8-K, and 10-KSB reports filed with the Commission.

OVERVIEW

We were incorporated under the laws of the State of Washington on May 31, 2000.
We develop, test and intend to commercialize solid organ transplantation
therapies based on an approach employing organ-specific precursor tissues. Our
future approach involves harvesting embryonic mammalian tissue at the earliest
stage at which stem cells commit to becoming organ-specific precursor tissues
and transplanting them in target human organ systems. The optimal window for
embryonic tissue transplantation was defined by Prof. Reisner's lab at the
Weizman Institute. We entered into a Research and License Agreement with Yeda
Research and Development Company Limited, which is located in Rehovot, Israel,
whereby Yeda procures the performance of research at the Weizman Institute of
Science, under the supervision of Professor Yair Reisner of the Department of
Immunology. We have a world wide license that shall expire in each country with
respect to each product at the later of (i) the expiration of the patents
covering such product in the country of sale, or (ii) 15 years from the date of
receipt of FDA New Drug Approval in the United States for such product, or the
equivalent in any other country in which the products are sold.

We are at development stage and devoting substantially all of our efforts toward
conducting R&D activities, raising capital, pursuing regulatory approval,
recruiting personnel and building infrastructure. Our former line of business
was selling bit error testers. Our license in connection with bit error testers
expired in May 2004.

SIGNIFICANT TRANSACTIONS AND EVENTS

CHANGE IN OWNERSHIP AND AMENDMENT OF LICENSE

Effective September 4, 2003, Lance Rudelsheim, the Company's former officer,
director and majority shareholder, closed on a share purchase agreement with
certain buyers pursuant to which the buyers, purchased 15,000,000 shares of the
then outstanding 18,036,000 shares of common stock of the Company for an
aggregate purchase price paid to the individual Seller of $10,000. In connection
with the consummation of the transaction, Lance Rudelsheim resigned as President
and sole director of the Company and appointed Mr. Robert G. Pico as the new
sole director of the Company and as the Company's Chief Executive Officer. In
connection with the transaction, the Company amended its license agreement with
Reach Technologies, Inc. The parties agreed that, in exchange for the
forgiveness of the remaining promissory note of $10,299 and all accrued interest
(approximately but not limited to $2,400) owed by the Company to Reach, the
Company agreed to convert its license to sell bit error rate testers from an
exclusive license to a worldwide non-exclusive license.

RESEARCH AGREEMENT

On October 8, 2003, we entered into a Research and License Agreement (the
"Research Agreement") with Yeda Research and Development Company Limited located
in Rehovot, Israel. The agreement relates to the rights of our company to have
the license from Yeda related to research conducted and to be conducted at the
Weizmann Institute of Science, under the supervision of Professor Yair Reisner
of the Department of Immunology, and relates to an invention comprising methods
of organ transplantation utilizing developing nephric and other tissues. The
License granted to us shall expire in each country with respect to each product
at the later of the following:

      o     the expiration of the patents covering such product in the country
            of sale; or

      o     15 years from the date of receipt of FDA New Drug Approval (in the
            United States), or the equivalent in any other country in which the
            products are sold.


                                       1
<PAGE>

In addition, Yeda may terminate the Research and License Agreement if we are in
breach thereof and Yeda may, at its option, terminate the Research and License
Agreement, in whole or in part, or make it non-exclusive if we fail to reach
certain commercialization and development goals as set out in the Research and
License Agreement. Yeda is entitled to unilaterally amend the license so that it
is non-exclusive or terminate the license in the event that we fail to achieve
commercialization of at least one product within certain time limits, fail to
commence various phases of clinical trials within certain time limits or fail to
sell a product after certain milestones. Further, if we contest the validity of
the patents, Yeda may terminate the license. In the event that Yeda would like
to pursue sponsored research with respect to, or the commercialization of, a
given product that would otherwise be subject to the Research and License
Agreement that we have not already commenced developing, then Yeda may provide
us with notice of its intention. Upon receipt of such notice, we will then have
thee months to submit a product development program. If we do not submit such
program, the license will be terminated with respect to said given product.
Finally, since the Company and Yeda did not come to an agreement regarding the
number of shares of common stock issuable upon exercise of the warrants, Yeda is
entitled to terminate the Research Agreement. Based on the parties' ongoing
negotiations, management is of the opinion that the parties will come to an
agreement, and Yeda will not terminate the license.

As part of the Research and License Agreement, the Company agreed to issue to
Yeda, by 120 days from the date of signature thereof, but which date Yeda
subsequently agreed to defer to no later than May 21, 2004, the following:

      o     a warrant, exercisable at an aggregate exercise price of US $900 to
            purchase up to 2.23% of the issued and outstanding shares of common
            stock of our company immediately following the exercise of such
            warrant; and

      o     a warrant, exercisable at an aggregate exercise price of US $1,100
            to purchase up to 2.67% of the issued and outstanding shares of our
            company immediately following the exercise of such warrant.

However, the Research and License Agreement provides that the maximum number of
shares of common stock that Yeda may exercise into for each warrant is 2,315,139
and 2,771,937, respectively (in each case as such number of shares of common
stock shall be appropriately adjusted in the event of stock splits, stock
dividends, capital reorganizations, reclassifications, recapitalizations and the
like as well as issuances or sales by us of shares for par value only, for
consideration less than par value and for no consideration, all in accordance
with the terms and conditions of said warrant, which shall be satisfactory to
Yeda and us). The share amounts described above are adjusted to reflect the
three for one split, but not the other adjustment events described above that
have occurred through the date hereof. We have applied to Yeda not to take into
account certain adjustment events in determining such maximum number of shares
as well as for a deferral of the date by which we are obligated to issue Yeda
the warrants. We are waiting for a formal response from Yeda regarding this
issue. Each such warrant shall be exercisable for a period beginning on the date
of its issuance and ending at the later of the following:

      o     one year following the termination of the Research and License
            Agreement; and

      o     ten years after the date of signature of the Research and License
            Agreement and to have such further terms and conditions as shall be
            satisfactory to us and Yeda.

We also agreed to pay or have paid to Yeda the following:

      o     with regard to the first year of the research period (commencing on
            April 9, 2003), we paid the amount of US $450,000 of which a
            non-refundable installment of US $450,000 was paid on December 23,
            2003. This amount is in addition to the $450,000 paid to Yeda in
            connection with researched performed by Yeda during the first year;

      o     with regard to the second year of research we owe an amount of US
            $900,000 of which we have paid $225,000 on April 23, 2004 and
            $225,000 on July 8, 2004; and

      o     with regard to the third year of the research period, we will pay an
            amount which shall be not less than US $900,000 and not more than US
            $1,000,000 per year to be determined by mutual agreement of the
            parties no later than 30 days prior to the commencement of the
            relevant year, in four equal three monthly non-refundable
            installments, payable in advance at the beginning of each three
            month period during such year.

If the parties fail to reach agreement within the time frame referred to above
regarding the amount of the research budget payable for the third year of the
research period (as the case may be), then the research budget for such year
shall be US $900,000 and Yeda shall procure the performance of research for such
reduced amount.

We have also agreed that within one year from the date of the Research and
License Agreement, we will submit a development program to Yeda for its
approval. The company has applied to Yeda for the deferral of the submission of
this program to September 2005. We are waiting for a formal response from Yeda
regarding this issue. We further undertook to use our best efforts to
commercialize the licensed products. We also agreed to pay Yeda a license fee as
follows:

      o     $50,000 per year commencing on April 9, 2006;
      o     4% of net sales of all products covered by the Research and License
            Agreement;
      o     33% of all sublicense fees for all agreements entered into within
            one year of the Agreement; and
      o     16% of all sublicense fees for all agreements entered into after
            such one year period.


                                       2
<PAGE>

RESULTS OF OPERATIONS - FISCAL QUARTER ENDED OCTOBER 31, 2003 COMPARED TO THE
FISCAL QUARTER ENDED OCTOBER 31, 2002

REVENUES AND COST OF GOODS SOLD

The Company is in its development stage therefore has no revenues and cost of
goods sold.

OPERATING EXPENSES

Operating expenses for the quarter ended October 31, 2003 amounted to $3,224.
The R&D expenses amounted to $2,079; the most significant R&D expense was
related to R&D activities performed by Yeda in the amount to $450. Cost related
to Option and warrants granted to employees and scientist associated with the
Company Research activities amounted to $1,543. The Company has General and
administrative expenses amounted to $1,145. The main expense related to General
and administrative expenses were attributed to warrants, options and shares
granted to service providers, employees and directors in the amount of $923. The
rest of the General and administrative expenses were attributed mainly to the
Company legal expenses and provision to D&O insurance.

EARNINGS (LOSS) FROM DISCONTINUED OPERATIONS OF A SEGMENT OF A BUSINESS

As a result of the disposal of its activities related to selling a bit error
rate tester, used for the integrity and reliability of communication channels
the Company has an earning of $13 in the quarter ending October 31, 2003
compared to a loss of $1 in the quarter ending October 31, 2002.

NET LOSS

As a result the Company incurred a net loss of $3,210 for the quarter ending
October 31, 2003, as compared to a net loss of $3 for the period ending October
31, 2002.

LIQUIDITY AND CAPITAL RESOURCES

The Company's cash and cash equivalents were $458 as of October 31, 2003,
compared to none as of October 31, 2002, this increase is attributed to funds
received on account of a private placement that the company is conducting. The
Company has a working capital of $348 as of October 31, 2003 compared to none as
of October 31, 2002. The Company plans to continue to finance its operations
through a combination of stock issuances, debt issuances, license payments and
research and development programs. There are no assurances, however, that the
company will be successful in obtaining an adequate level of financing required
for the long-term development and commercialization of its planned products.

ITEM 3. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, our company conducted an
evaluation, under the supervision and with the participation of our acting chief
executive officer and chief financial officer, of our disclosure controls and
procedures (as defined in Rule 13a-15(e) and of the Exchange Act). Based upon
this evaluation, our acting chief executive officer and chief financial officer
concluded that there were material weaknesses with our disclosure controls and
procedures in so far as they were not effective in gathering, analyzing and
disclosing information needed to satisfy our disclosure obligations under the
Exchange Act.

As a result of the above, the Company reorganized its executive personnel to
address these issues. In connection with the reorganization, the Company is
developing procedures, forms, checklists and reporting packages to address these
deficiencies, and management believes progress had been made to improve the
Company's system of internal controls. However, despite management efforts there
continues to exist material weaknesses in the Company's internal controls.
Management believes additional progress in strengthening its internal controls
will continue through the end of the second quarter of 2005.


                                       3
<PAGE>

                           PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company may become involved in various lawsuits and legal
proceedings which arise in the ordinary course of business. However, litigation
is subject to inherent uncertainties, and an adverse result in these or other
matters may arise from time to time that may harm the Company's business. Except
for the following, the Company is currently not aware of nor has any knowledge
of any such legal proceedings or claims that we believe will have, individually
or in the aggregate, a material adverse affect on our business, financial
condition or operating results:

      o     On July 19, 2004, an investor which participated in the Company's
            private placement of securities in March 2004, sent a letter to the
            Company claiming that it was a victim of the Company's misconduct.
            The letter was subsequently withdrawn on July 29, 2004;

      o     On September 30, 2004, an investor which participated in the
            Company's private placement of securities in March 2004, sent a
            letter to the Company claiming that it was prepared to bring claims
            in the United States District Court for the Southern District of New
            York if compromise negotiations were not commenced and concluded
            without delay. The Company has commenced compromise negotiations
            with all of the investors from the March 2004 private placement; and

      o     On October 4, 2004, the Company received a demand letter to execute
            an oral lease agreement of the Company's previous premises. Based on
            the opinion of the management and its legal advisors, the Company
            has reasonably good defense, and as a result, no provision was
            recorded in the financial statements; and

      o     The Company received a demand from a broker in relation to the
            Company's capital raising to receive $30,000 as a fee. The Company's
            management and its legal advisors, are of the opinion that the
            Company has good defense, and, as a result, no provision was
            recorded in the financial statements.

      o     On September 7, 2004, certain shareholders demanded from the former
            CEO to repay the Company the amount of $ 1,074,00 (which is the
            value of the shares, that the Company issued as a result of the
            CEO's cashless exercise of the abovementioned options, at the date
            of exercise, and which were sold by the CEO), claiming that the
            exercise of the options was executed before the end of the vesting
            period. In addition, the above shareholders demanded that the former
            CEO pay the company, compensation in the amount of $ 645,000 for
            damages. Management of the Company and its legal advisors are of the
            opinion that the vast majority of the assertions are against the
            former CEO and not the Company. The Company denies assertions that
            may imply to its responsibility and, as a result, no provision was
            recorded in the financial statements.

ITEM 2. CHANGE IN SECURITIES

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

31.1 Certification of the Chief Executive Officer of Tissera, Inc. pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of the Chief Financial Officer of Tissera, Inc. pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification of the Chief Executive Officer of Tissera, Inc. pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of the Chief Financial Officer of Tissera, Inc. pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.


                                       4
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this Form
10-QSB Report, for the Quarter ended October 31, 2003 has been signed below by
the following person on behalf of the Registrant and in the capacity and on the
date indicated.

January 18, 2005

                                             TISSERA, INC.

                                             By    /s/Amos Eiran
                                                -------------------------------
                                                   Amos Eiran
                                                   Chief Executive Officer

                                             By    /s/Alex Werber
                                                -------------------------------
                                                   Alex Werber
                                                   Chief Financial Officer


                                       5